المؤلفون: Gietema, JA, Hoekstra, R (Rosa), de Vos, FYFL, de Vries, EGE, Uges, DRA, van der Gaast, Ate, Groen, HJM, Loos, Walter, Knight, RA, Karyekar, CS, Daskowski, D, McKeegan, E, Knight, R, Humerickhouse, R, Verweij, Jaap, Eskens, Ferry

المساهمون: Groningen Research Institute of Pharmacy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology

المصدر: Annals of Oncology, 17(8), 1320-1327. Oxford University Press
Annals of Oncology, 17, 1320-1327. Elsevier Ltd.

مصطلحات موضوعية: Adult, Male, Bevacizumab, CELL LUNG-CANCER, medicine.medical_treatment, BEVACIZUMAB, cisplatin, Angiogenesis Inhibitors, PACLITAXEL, Pharmacology, Deoxycytidine, LEUCOVORIN, Thrombospondin 1, Pharmacokinetics, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Drug Interactions, Aged, Cisplatin, Chemotherapy, business.industry, gemcitabine, ABT-510, Hematology, Middle Aged, phase I, Chemotherapy regimen, RANDOMIZED-TRIAL, FLUOROURACIL, Gemcitabine, SU5416, METASTATIC COLORECTAL-CANCER, angiogenesis inhibitor, Oncology, Fluorouracil, Female, business, Oligopeptides, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d734c24e74dad1fadaf87c42dad5b107
https://doi.org/10.1093/annonc/mdl102